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Abstract
Background: Previous studies have shown that the expression of tissue factor pathway inhibitor-
2 (TFPI-2), a matrix-associated Kunitz-type serine proteinase inhibitor, is markedly down-regulated
in several tumor cells through hypermethylation of the TFPI-2 gene promoter. In the present study,
RT-PCR analysis of total RNA from both human normal and tumor cells revealed a novel 289
nucleotide splice variant of the TFPI-2 transcript designated as aberrantly-spliced TFPI-2 (asTFPI-2).
Results: Nucleotide sequence analyses indicated that asTFPI-2 consists of complete exons II and
V, fused with several nucleotides derived from exons III and IV, as well as six nucleotides derived
from intron C. 5'- and 3'-RACE analyses of total RNA amplified exclusively the wild-type TFPI-2
transcript, indicating that asTFPI-2 lacks either a 5'-untranslated region (UTR) or a 3'-poly (A)+ tail.
Quantitative real-time RT-PCR analyses revealed that several human tumor cells contain 4 to 50-
fold more copies of asTFPI-2 in comparison to normal cells. In spite of the absence of a 5'-UTR or
poly (A)+ tail, the asTFPI-2 variant exhibited a half-life of ~16 h in tumor cells.
Conclusion: Our studies reveal the existence of a novel, aberrantly-spliced TFPI-2 transcript
predominantly expressed in tumor cells and provides suggestive evidence for an additional
mechanism for tumor cells to down-regulate TFPI-2 protein expression enhancing their ability to
degrade the extracellular matrix.
Background
Tissue factor pathway inhibitor-2 (TFPI-2) is a 32 kDa
Kunitz-type serine proteinase inhibitor synthesized by a
variety of cells and directionally secreted into their extra-
cellular matrix (ECM) where it is thought to regulate plas-
min-mediated ECM degradation and remodeling
(reviewed by Chand et al. [1]). As matrix degradation is an
important step in tumor invasion and metastasis, several,
but not all, tumor cells downregulate TFPI-2 expression
[2,3]. In this regard, overexpression of TFPI-2 in several
tumor cells was shown to inhibit their growth, invasive-
ness, angiogenic potential and metastatic potential [4-9].
The mechanism whereby some tumor cells downregulate
TFPI-2 synthesis has been primarily attributed to tran-
scriptional silencing through hypermethylation of CpG
sites in the TFPI-2 promoter [10-14], inasmuch as treat-
ment of these tumor cells with a methyltransferase inhib-
itor, 5'-aza-2'-deoxycytidine, restored TFPI-2
transcription[14]. In addition, several highly aggressive
tumors delete the locus for the TFPI-2 gene in the chromo-
some 7q region [15-17], resulting in the total loss of TFPI-
2 protein expression in these cells. Accordingly, the TFPI-
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2 gene is becoming increasingly recognized as a tumor
suppressor gene, since its down-regulation in several types
of cancers allow for enhanced tumor growth and metasta-
sis.
In view of its apparent role in cancer progression, we ini-
tiated a study to quantify TFPI-2 transcript levels in total
RNA samples from selected normal human tissue, as well
as their corresponding tumor tissue. In the course of these
studies, we detected a novel, aberrantly-spliced variant of
TFPI-2 mRNA derived from TFPI-2 pre-mRNA splicing at
exon/intron boundaries, as well as at new sites within
exons and introns. The levels of the aberrantly-spliced var-
iant of TFPI-2 were either very low or undetectable in nor-
mal tissue, but markedly upregulated in tumor tissues and
several tumor cell lines. These findings provide suggestive
evidence for an additional mechanism for tumor cells to
down-regulate TFPI-2 expression through aberrant splic-
ing.
Results
Novel TFPI-2 splice variant generated by aberrant splicing
In preliminary studies designed to assess the levels of
TFPI-2 transcripts in various normal and tumor tissues,
co-amplification of a lower molecular weight cDNA was
observed following RT-PCR of total RNA. The low Mr
cDNA was faintly visible in normal tissues (lung, colon
and liver), but was markedly upregulated in the corre-
sponding tumor tissues. Nucleotide sequence analyses of
the low Mr cDNA amplified from the total RNA of lung
tumor tissue revealed a novel, 289 nucleotide, aberrantly-
spliced form of the TFPI-2 transcript designated as asTFPI-
2 (Fig. 1B). Subsequent studies revealed that the nucle-
otide sequence of the low Mr cDNA from HepG2 cells was
identical to that observed in lung tumor tissue (data not
shown). Both 5' and 3' RACE analyses of total RNA
derived from several tissues and cell lines tested resulted
exclusively in the amplification of the normal TFPI-2 tran-
script. In these RACE analyses, several attempts were made
to identify any 5' and 3'-untranslated regions (UTRs) by
varying reaction conditions and using different sets of
primers, but each attempt only amplified the 5' and 3'
ends of normal TFPI-2 (data not shown). Moreover, the 5'
and 3' boundaries of the asTFPI-2 were also assessed by
primer walking studies using a series of primer combina-
tions spanning the entire regions of exon I, intron A and
the 3' UTR (Fig. 1). Thus, these results indicate that the
aberrantly-spliced asTFPI-2 reported here lacks any
unique 5' and 3'-UTRs and consists of complete exons II
and V, fused with 14 nucleotides derived from exon III, 7
nucleotides derived from exon IV, and 6 nucleotides of
intron C (Fig. 1A).
The levels of asTFPI-2 are elevated in tumor tissues and 
tumor cell lines
An apparent variation in the transcripts levels of TFPI-2
and asTFPI-2 from primary cells and tumor cells was
observed by semi-quantitative RT-PCR, and subsequently
validated by quantitative real-time RT-PCR analysis. Semi-
quantitative RT-PCR was carried out using common set of
primers to amplify TFPI-2 and asTFPI-2 transcripts in a
single reaction (Fig. 2A). The relative intensity data of each
amplicon derived was normalized using the cyclophilin A
transcript (Fig. 2B). The quantiscan analysis of each
amplicon indicated, on average, that there are ~10 fold
more TFPI-2 copies in normal tissue in comparison to
tumor tissues, and that TFPI-2 is absent in many tumor
cell lines (HepG2, Capan-2 and Colo-205). In contrast,
with the exception of the J82 bladder carcinoma cell line,
there are 7-fold more copies of the asTFPI-2 splice variant
in all tumors compared to their corresponding normal tis-
sues or normal cultured cell lines (Fig. 2C).
Quantitative real-time RT-PCR analyses were performed
separately for TFPI-2 and asTFPI-2 using specific primers
(see Materials and methods). The copy numbers for TFPI-
2, asTFPI-2 and cyclophilin A transcripts were derived
from standard curves of their respective plasmids. The
copy numbers of both TFPI-2 and asTFPI-2 observed were
normalized to 102  copy numbers of cyclophilin A in
respective samples (Fig. 3). A strong linear relationship
between the Ct and the log of the number of copies was
consistently demonstrated (R2 ≥ 0.99), and melting curves
confirmed the presence of a single amplicon. The data
analyses of results from three independent measurements
revealed highly variable amounts of TFPI-2 and asTFPI-2
transcripts between normal and tumor cells, but on aver-
age, there are 10-fold more TFPI-2 copies in normal tissue
compared to tumor tissues, whereas there are 53-fold
more copies of asTFPI-2 splice variant in tumor tissue or
tumor cell lines compared to normal tissues or cultured
cell lines. In general, normal tissues and cell lines con-
tained higher levels of full-length TFPI-2 while tumor tis-
sues and tumor cell lines, with the exception of the
bladder carcinoma J82 cell line, contained 4–50 fold
higher levels of the asTFPI-2 transcripts. In the case of pla-
centa, asTFPI-2 transcripts were undetectable. The data
presented in Figures 2 and 3 reflect an average of three
independent experiments.
Stability of asTFPI-2
It has been shown in numerous reports that actinomycin
D inhibits cell proliferation by forming a stable complex
with single-stranded DNA and blocking the movement of
RNA polymerase that interferes with DNA-dependent
RNA synthesis [18]. To assess the stability of the full-
length TFPI-2 and asTFPI-2 transcripts, the transcription
inhibitor actinomycin D was added to HUVEC and Colo-Molecular Cancer 2007, 6:20 http://www.molecular-cancer.com/content/6/1/20
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205 cells, and the total RNA was extracted at selected inter-
vals. The copy numbers of the TFPI-2 and asTFPI-2 tran-
script were measured by real-time RT-PCR in order to
compare the rate of mRNA decay in these two cell lines
(Fig. 4). As shown in Fig 4, a half-life value of ~16 h was
obtained for asTFPI-2 in a colon carcinoma cell line, in
comparison to ~8 h for TFPI-2 mRNA in HUVECs. At this
point, the functional significance of these relative values is
difficult to interpret, given that they were obtained in dif-
ferent cell lines out of necessity due to the lack of a single
cell line that produces each of these transcripts in suffi-
cient quantities. Nonetheless, these findings provide sug-
gestive evidence that the half-life of asTFPI-2 may be
significantly longer than TFPI-2 mRNA in cultured cells.
Northern blot analysis
To confirm the presence of TFPI-2 and asTFPI-2 transcripts
in a normal (HUVEC) and a tumor (Colo-205) cell line,
we performed Northern hybridizations using an asTFPI-2
specific cDNA radiolabeled probe. The analysis revealed a
major 1.2-kb transcript as well as a minor 1.8-kb tran-
script in HUVECs (Fig. 5), as reported earlier [19]. TFPI-2
A schematic representation of the full-length TFPI-2 gene and a novel TFPI-2 splice variant Figure 1
A schematic representation of the full-length TFPI-2 gene and a novel TFPI-2 splice variant. (A) The full-length 
TFPI-2 gene consists of 5 exons (designated by roman numerals) and 4 introns (designated by letters). (B) The novel splice var-
iant reported here is generated by splicing of complete exon II, 15 nucleotides of exon III (AAAGTTCCCAAAGTT), 6 nucle-
otides of (GAATCC) intron C, 7 nucleotides of exon IV (GCAAAAG) and complete exon V. (B) The complete (289 bp) 
asTFPI-2 cDNA sequence is shown in 5' to 3' orientation. (C) The nucleotide sequences at the splice site junctions that result 
in the generation of asTFPI-2. The arabic numbers in the TFPI-2 gene diagram (A) correspond to the splice site locations. Splice 
site numbers 1–3 and 8–9 have normal consensus splice sites, whereas sites 4–7 and 10 are non-consensus splice sites. The 
intronic sequences are presented in lower case letters, while the exonic sequence is presented in upper case letters.
asTFPI-2 (289 residue) sequence
AGGAAATAAC  GCGGAGATCT  GTCTCCTGCC  CCTAGACTAC  GGACCCTGCC  GGGCCCTACT   TCTCCGTTAC 
TACTACGACA   GGTACACGCA  GAGCTGCCGC CAGTTCCTGT  ACGGGGGCTG  CGAGGGCAAC GCCAACAATT 
TCTACACCTG  GGAGGCTTGC  GACGATGCTT  GCTGGAGGAT  AGAAAAAGTT CCCAAAGTTG  AATCCGCAAA 
AGCTTTGAAA  AAGAAAAAGA  AGATGCCAAA  GCTTCGCTTT GCCAGTAGAA  TCCGGAAAAT TCGGAAGAAG  
CAATTTTAA
asTFPI-2
TFPI-2 gene 
A
B
C
Splice sites
1. gaggaagacggggaagaag-UCCUUU 2. CUCCUAUCUUU-cauuca 3. ggaggaaaaggauc-UUCAAG
4. GUUUCAA-ACGGCCGU 5. ugggga-cuuagg 6. cuuagg-aacuuuac
7. UGCACGUACA- CGUUU 8. UUUUC-caucacuu 9. uaacuaaaauc-GAAACUUUU
10.UUAAAAUU-uguaagaauu
3′ 5′
I II III IV V
A B C D
1 2 3 4 5 6 7 8 9 10Molecular Cancer 2007, 6:20 http://www.molecular-cancer.com/content/6/1/20
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Relative quantitation of human TFPI-2 transcripts in various normal and tumor cells Figure 2
Relative quantitation of human TFPI-2 transcripts in various normal and tumor cells. Agarose gel electrophoresis 
analysis of RT-PCR products from various cells and tissues. Panel A depicts TFPI-2 (622 bp) and asTFPI-2 (289 bp) transcripts, 
while panel B depicts cyclophilin A transcripts. The data presented in panel C represents the amount of transcripts normalized 
to 10,000 arbitrary units of cyclophilin A amplified from each sample. Each column represents the average of two amplification 
reactions (error bars represent standard deviation) performed on a single cDNA sample reverse-transcribed from RNA 
derived from each sample.
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transcript was not detectable in Colo-205 cells, whereas
the asTFPI-2 (~300 bp) transcript was readily observed in
these cells (Fig. 5).
TFPI-2 protein levels in normal and tumor cell lines
Despite the apparent absence of 5' and 3'-UTRs in asTFPI-
2, we could not rule out the possibility that the asTFPI-2
transcript was translated within tumor cells by some novel
mechanism, and that the putative translated product
played some role in tumor biology. Accordingly, expres-
sion of TFPI-2 immunoreactive protein in lysates of two
normal and five cancer cell lines was analyzed by immu-
noblotting using an anti-TFPI-2 polyclonal antibody
raised against recombinant human α-TFPI-2 (Fig. 6). As
expected, TFPI-2 protein was detected in HUVECs and WI-
38 human fibroblast cell lysates, and migrated with the
characteristic triplet pattern representing α, β and γ differ-
entially glycosylated forms of TFPI-2 [20]. However, no
immunoreactive protein was observed at the expected Mr
of ~11 kDa for asTFPI-2 in any of the cell lines examined
(Fig. 6). It is also noteworthy that no immunoreactive
protein was observed in J82 cells lysates, despite the rela-
tively high copy numbers of TFPI-2 observed in these cells
by quantitative real-time RT-PCR (Fig. 3). In addition,
using primers specific for the 5'-UTR and poly (A)+ tail of
TFPI-2, a full-length transcript for TFPI-2 was observed in
J82 cells (data not shown). Precisely why J82 cells do not
synthesize TFPI-2 protein will require additional studies,
but it is conceivable that the full-length TFPI-2 transcript
in these cells contains one or more mutations that pre-
cludes translation.
Discussion
Human TFPI-2, an ECM-associated Kunitz-type serine
proteinase inhibitor [21], is thought to play a significant
role in the regulation of plasmin-mediated ECM degrada-
tion during tumor cell invasion and metastasis, wound
healing, and angiogenesis. Proteolytic degradation of the
extracellular matrix, one of the key events in the process of
tumor invasion and metastasis, depends on a delicate bal-
Quantitative real-time RT-PCR analyses of human TFPI-2 transcripts in normal and tumor samples Figure 3
Quantitative real-time RT-PCR analyses of human TFPI-2 transcripts in normal and tumor samples. The copy 
numbers of TFPI-2 and asTFPI-2 in several selected samples were determined and normalized to 102 copies of cyclophilin in 
each sample. The copy numbers were interpolated from standard curves correlating the threshold cycle number (Ct values) 
and copy numbers of TFPI-2 and asTFPI-2. Each column represents the average of three amplification reactions (error bars 
represent standard deviation) performed on a single cDNA sample reverse-transcribed from RNA derived from each sample.
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ance of matrix-degrading proteinases and their inhibitors.
The TFPI-2 transcript is abundant in the full-term pla-
centa, and is also present at various levels in several adult
human tissues, such as liver, lung, skeletal muscle, heart,
kidney, and pancreas [22]. Conversely, TFPI-2 mRNA lev-
els fall with increasing malignancy in the case of breast,
gastric, colon, pancreatic, laryngeal, renal, endometrial,
glial and several other human malignant tumors
[3,23,24].
In experiments designed to quantify TFPI-2 transcripts in
human normal and corresponding tumor tissues using
RT-PCR, we observed two TFPI-2 amplicons, using exon II
(sense) and exon V (anti-sense) primers. Nucleotide
sequencing analysis of both amplicons revealed that the
larger Mr amplicon (622 bp) corresponded to the full-
length TFPI-2 cDNA, while the smaller Mr cDNA (289 bp)
was an aberrantly-spliced form of the TFPI-2 transcript,
which we have provisionally designated as asTFPI-2.
Primer walking with a series of primer combinations
spanning the entire regions of exon I, intron A and 3' UTR
revealed that the complete asTFPI-2 transcript consisted of
exon II and exon V, with three unusual spliced regions of
nucleotides from exon III, intron C, and exon IV tandemly
interspersed (Fig. 1A). Analysis of potential consensus
splice sites in the TFPI-2 gene (GenBank accession
no.AF217542) utilized for the generation of asTFPI-2
using splice site predictor [39] revealed no consensus
splice sites for subsequent insertion of the observed nucle-
otide sequences of exon III, intron C and exon IV between
exons II and V (Fig. 1C). It is, therefore, highly likely that
asTFPI-2 is an aberrant splice product generated from
TFPI-2 pre-mRNA in which the splicing of pre-mRNA is
misdirected and does not occur solely at de facto splice
sites normally used by the major, U2-dependent spliceo-
some [25].
In order to assess the relative levels of the TFPI-2 and asT-
FPI-2 transcripts, we used semi-quantitative RT-PCR and
quantitative real-time PCR and observed a dramatic differ-
ence in the levels of these two transcripts in normal cells
and tumor cells. Quantification of TFPI-2 mRNA and asT-
FPI-2 levels using real-time PCR was found to be highly
reproducible using transcript-specific primers, with low
inter-assay variations. By this procedure, normal cells syn-
thesize ~10-fold more wild-type TFPI-2 transcripts than
tumor cells, whereas tumor cells synthesized 4–50 times
more asTFPI-2 than normal cells. Moreover, the propor-
tion of asTFPI-2 to that of wild-type TFPI-2 was 7–12-fold
Northern blot analysis of human TFPI-2 transcripts in normal  and tumor cells Figure 5
Northern blot analysis of human TFPI-2 transcripts 
in normal and tumor cells. Total RNA from HUVEC and 
Colo-205 cells was extracted and equal amounts (20 µg) of 
RNA was electrophoresed in a 1.2% agarose-formaldehyde 
gel and subsequently transferred to a nylon membrane and 
probed with 32P-asTFPI-2 cDNA. RNA molecular weight 
markers are indicated on the left. The probe detected both 
major (1.2 kb) and minor (1.8 kb) TFPI-2 transcripts in the 
case of HUVECs, and approximately a 300 bp asTFPI-2 tran-
script in Colo-205 cells.
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Stability of TFPI-2 and asTFPI-2 transcripts Figure 4
Stability of TFPI-2 and asTFPI-2 transcripts. HUVECs 
and Colo-205 cells were treated with 5 µM actinomycin D 
for various durations to block transcription. Total RNA was 
extracted at the indicated time points following the addition 
of actinomycin D, and quantitative real-time RT-PCR amplifi-
cation were performed as described in the text to determine 
copy numbers of each TFPI-2 mRNA. Each data-point repre-
sents the average of three amplification reactions performed 
on a single cDNA sample reverse-transcribed from RNA 
derived from each sample.
Time (hr)
0 5 10 15 20 25
A
r
b
i
t
r
a
r
y
 
U
n
i
t
s
 
(
A
U
)
10
100
1000
10000
TFPI-2
as TFPI-2Molecular Cancer 2007, 6:20 http://www.molecular-cancer.com/content/6/1/20
Page 7 of 11
(page number not for citation purposes)
higher in tumor cells, while in normal cells, the asTFPI-2
transcript was very low to negligible (Fig. 2 and 3).
An unusual feature of the asTFPI-2 is its lack of detectable
5' – and 3' UTRs. As expected, both 5' and 3'-RACE analy-
ses of total RNA from either normal tissue (placenta) or a
tumor sample (lung tumor) resulted in a single amplifica-
tion product containing the 5'-UTR and 3' – poly (A)+ tail
regions of wild-type TFPI-2 cDNA. However, no addi-
tional RACE amplification product(s) with either a 5'-UTR
or a 3'-poly (A)+ tail was observed in either lung tumor
RNA or placental RNA, indicating that the asTFPI-2 tran-
script lacked these two elements. In addition, application
of HUVEC and Colo-205 total RNA samples to oligo-dt
columns with subsequent elution of the poly (A)+ RNA
and RT-PCR analyses of these elutes resulted exclusively in
the amplification of the full-length TFPI-2 transcript (data
not shown). Thus, either by message enrichment, RACE
analyses and primer walking experiments, we conclude
that asTFPI-2 does not contain either a 5'-UTR or a 3'-poly
(A)+ tail. Moreover northern blot analysis of total RNA
obtained from Colo-205 cells revealed that only the asT-
FPI-2 transcript (~300 bp) was observed in these cells, fur-
ther validating the RT-PCR results (Fig. 5). In contrast, two
high molecular weight transcripts (1.2 kb and 1.8 kb) for
full length TFPI-2 were observed in HUVECs, confirming
the results of previous studies [19].
After treating cells with actinomycin D, the TFPI-2 mRNA
exhibited a half-life of ~8 h in HUVECs, whereas the asT-
FPI-2 mRNA exhibited a half-life value of ~16 h in Colo-
205 cells (Fig. 4). Although it is difficult to directly com-
pare the half-lives of these two transcripts made in normal
and transformed cells, the relatively long half-life of the
asTFPI-2 transcript is remarkable when one considers that
it lacks both a 5'-UTR and 3'-poly (A) tail, two elements
that usually offer some protection from exonucleolytic
decay [26]. Inasmuch as asTFPI-2 is apparently not trans-
lated and exhibits a relatively long half-life, it is tempting
to speculate that this splice variant plays some role in
tumor homeostasis and studies to address this possibility
are ongoing in our laboratory.
Our results are consistent with several reports on differen-
tial alternative splicing between cancer and normal
expressed sequence tag libraries where there appears to be
a higher proportion of disrupted spliced variants in tumor
suppressor genes than in non-cancer-related genes [27-
29]. In this regard, aberrant splicing has been reported for
mdm2, TSG101 and FHIT pre-mRNAs [25,30], exclusively
Immunoblot analysis of TFPI-2 expression in normal and tumor cell lines Figure 6
Immunoblot analysis of TFPI-2 expression in normal and tumor cell lines. Cell lysate samples were analyzed by 
immunoblotting using a polyclonal rabbit antibody raised against recombinant human α-TFPI-2 (upper panel). Alpha-tubulin 
expression (lower panel) was also assessed in the same lysate samples to establish equivalent loading volumes.
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in tumors, and the splicing was characterized by either
losses of individual exons, or loss of exons with insertions
of unknown DNA sequences without regard for proper
splice junctions [31]. Increased aberrant splicing also rep-
resent an additional mechanism for the reduction of the
amount of wild type tumor suppressor mRNA without
mutation, as shown for the NF1 gene [32], or alternative
splicing, as shown for a brain-specific exon in Bin1 elimi-
nating the activity of the tumor suppressor in melanoma
[33]. In addition, several cases of aberrant and alternative
splicing of different proteins such as transcription factors,
signal transducers and extra-cellular matrix components
have been related to tumor cell growth [34]. As a conse-
quence, a number of interventions that either alter or
exploit alternative splicing are currently under active
investigation for cancer therapy [35,36]. Conceivably,
detection of asTFPI-2 could find application in tumor
diagnosis, or possibly serve as a marker for cancer progres-
sion.
Our laboratory, as well as others, have previously reported
that overexpression of candidate tumor suppressor TFPI-2
gene in several highly metastatic tumor cells markedly
inhibits their growth and metastasis in-vivo by regulating
pericellular extracellular matrix (ECM) remodeling and
angiogenesis [4-10]. Conversely, hypermethylation of
tumor suppressor genes is a major epigenetic change that
contributes to tumor progression and is correlated with
transcriptional silencing. Hypermethylation of the TFPI-2
gene promoter has been described recently as a possible
mechanism for gene silencing in a limited number of
tumor cell lines [3,10-12,37]. However, the prevalence of
hypermethylation of the TFPI-2 promoter in primary
tumors has not been systematically investigated. In many
cancer cells, the hypermethylation of the TFPI-2 promoter
does not appear to be the sole basis for TFPI-2 gene silenc-
ing, as one or more components of the cellular transcrip-
tion machinery that regulates TFPI-2 expression may also
be hypermethylated leading to their silencing as well [13].
The existence of an aberrantly-spliced variant of TFPI-2
that is untranslated, and appears to be highly upregulated
in tumor cells, suggests an additional, novel mechanism
for further downregulation of TFPI-2 expression in tumor
cells.
Conclusion
The results obtained in this study strongly suggest an addi-
tional mechanism in tumor cells to down regulate TFPI-2
expression by aberrant splicing. The existence of a novel
TFPI-2 transcript predominantly in tumor cells has not
been previously reported. While the present study sug-
gests a direct correlation between the production of a
novel TFPI-2 transcript and tumor development, further
studies are needed to determine whether the alternative
splicing of TFPI-2 pre-mRNA reported here is associated
with tumor progression.
Methods
Materials
The human tumor cell lines J-82 (bladder cell carcinoma),
Capan-2 (pancreatic adenocarcinoma), HepG2 (hepato-
cellular carcinoma), HT-1080 (fibrosarcoma), Colo-205
(colon adenocarcinoma), and HEK 293 (primary embry-
onal kidney), were obtained from American Type Culture
Collection (Manassas, VA). The human embryonic fibrob-
last cell line WI-38 was kindly provided by Dr. LVM Rao
(University of Texas, Tyler, TX). Human umbilical vein
endothelial cells (HUVECs) were obtained from Cambrex
(Walkersville, MD). Dulbecco's minimal essential
medium (DMEM), penicillin, and streptomycin, actino-
mycin D and mouse monoclonal anti-tubulin antibody
were purchased from Sigma-Aldrich (St Louis, MO). Fetal
bovine serum was purchased from Hyclone (Ogden, UT).
RNEasy® RNA extraction kit, Oligotex mRNA mini kit, and
Plasmid Spin Miniprep kit were purchased from Qiagen
(Valencia, CA). Normal human lung, liver and colon
RNAs, as well as their corresponding tumor RNAs, were
purchased from Chemicon Inc. (Temecula, CA). Human
placental total RNA and SMART® RACE kit was purchased
from BD Biosciences Clontech (Palo Alto, CA). RT-PCR
kit TaqMan® and SYBR®-green PCR Master Mix were pur-
chased from Applied Biosystems (Foster City, CA). Accu-
Prime™ Pfu Polymeras and DNase-I were purchased from
Invitrogen (Carlsbad, CA). Nylon membrane, Nitrocellu-
lose (NC) membranes and goat anti-rabbit IgG-HRP were
purchased from Bio-Rad (Hercules, CA). Random primed
labeling kit was purchased from Roche diagnostics (Indi-
anapolis, IN). PCR-Script™ AMP cloning kit and E. coli
XL1 Blue cells were from Stratagene (Cedar Creek, TX).
Chemiluminescent HRP substrate was purchased from
Millipore Corporation (Billerica, MA).
Cell culture and total RNA preparation
All cell lines were maintained in Dulbecco's minimal
essential medium (DMEM), supplemented with 10% fetal
bovine serum and penicillin-streptomycin. The cells were
cultured at 37°C in a humidified atmosphere containing
6% CO2, and approximately 5 × 106 cells were processed
for total RNA isolation. The total RNAs were purified
using the RNEasy® RNA extraction kit according to the
manufacturer's instruction. All purified RNA samples
were further digested with to ensure complete removal of
any contaminating genomic or mitochondrial DNA. The
DNase-I was subsequently inactivated by incubation with
2 mM EDTA at 65°C for 15 min. Total RNA samples from
HUVECs and Colo-205 cells were also subjected to further
purification on oligo-dt columns (Oligotex) to obtain
poly (A)+ RNA.Molecular Cancer 2007, 6:20 http://www.molecular-cancer.com/content/6/1/20
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Rapid amplification of cDNA 5' and 3'ends (5'-and 3'-
RACE)
The corresponding first-strand cDNAs were prepared from
1 µg of total RNA, using the PowerScript reverse tran-
scriptase, 5'-CDS® primer (modified oligo-dT primer) and
BD™ SMART IIA® primer using the BD™ SMART® RACE
cDNA amplification kit. Dilutions of each 5' and 3' RACE-
ready cDNAs were used in PCR amplification reactions
with the SMART®  RACE kit universal primer mix and
either gene-specific antisense exon IV primers (5'-TAC TTT
TCT GTG GAC CCC TCAC-3'), to amplify TFPI-2, or exon
V primer (5'-TTG CTT CTT CCG AAT TTT CCG G-3') to
amplify 5' ends of both TFPI-2/asTFPI-2. Alternatively asT-
FPI-2 specific primer (5'-CTT TTG CGG ATT CAA C-3')
was also used in combination with the universal primer
mix. The exon II sense primer was used to amplify 3' ends
(5'-AAC GCC AAC AAT TTC TAC ACC T-3') in combina-
tion with the universal primer mix. The 5' and 3' RACE
cDNAs syntheses and PCR amplifications were performed
according to the manufacturer's instruction.
Nucleotide sequencing analysis
A series of oligonucleotide primers spanning from the cap
region (FT2-CAP), exon I (FT2-SP1, FT2-Ex1A, FT2-Ex1B,
FT2-Ex1C), intron A (FT2-Int1A, FT2-Int1B), exon II (FT2-
Ex2), and exon V (RT2-R1) and 3'-UTR (RHT-OD, RT2-
PAT), of the TFPI-2 gene were designed to identify the 5'
and 3' boundaries of the asTFPI-2 transcript (Table 1). The
PCR amplicons obtained from the primer set (FT2-Ex2 as
sense and RHT-OD as antisense primers) were ligated into
pPCR-Script™ AMP cloning vector and transformed into
competent XL1 Blue cells. Plasmid DNAs were prepared
from individually selected clones, using a Plasmid Spin
Miniprep kit, and vector primers were used to for sequenc-
ing the inserts. The nucleotide sequence was determined
by the dideoxy chain termination method using the
BigDye Terminator Cycle Sequencing Kit in a Model 377
Sequencing System (Applied Biosystems).
Semi-quantitative RT-PCR of TFPI-2 transcripts
The first strand cDNAs were prepared from 2 µg of total
RNA using random hexamers and a reverse transcriptase-
PCR (RT-PCR) kit in a total volume of 50 µl. The TFPI-2
and asTFPI-2 transcripts were amplified using a common
sense primer (5'-AGG AAA TAA CGC GGA GAT CTG TCT-
3') and a common antisense primer (5'-TTAAAATTGCT-
TCTTCCGAAT-3'). The constitutively expressed endog-
enous housekeeping gene, cyclophilin A (using sense
primer 5'-GTCTCCTTTGAGCTGTTTGC-3' and antisense
primer 5'-AAGCAGGAACCCTTATAACC-3') was also
amplified in separate tubes. The controlled semi-quantita-
tive RT-PCR assays were performed using 1 µl of first-
strand cDNA product and AccuPrime™ Pfu polymerase in
a total volume of 50 µl. PCR conditions were 1 cycle of
94°C for 2 min; 30 cycles of 94°C for 30 sec (denatura-
tion), 60°C for 30 sec (annealing) and 68°C for 1 min
(extension) followed by 1 cycle of 68°C for 5 minutes
(final extension). Aliquots of all PCR products were ana-
lyzed in 2% agarose gels and visualized with 0.1 mg/ml
ethidium bromide staining. The relative intensity of each
amplicon was quantified using Quantiscan software (Bio-
soft™) and intensities are reported in arbitrary units
(A.U.). The intensity of each amplicon was normalized to
10,000 A.U. levels of cyclophilin A amplified from each
sample.
Splice variant-specific quantitative RT-PCR
A two-step, quantitative real-time RT-PCR was performed
in triplicate using an ABI Prism 7000 Sequence Detection
System (Applied Biosystems) with standard temperature
protocol and 2x SYBR Green PCR Master Mix reagent in a
total volume of 25 µl. The first-strand cDNAs were pre-
pared from 1 µg of total RNA in a final volume of 50 µl
using random hexamers and a reverse-transcriptase PCR
kit. For absolute quantitation, the PCRScript-TFPI-2 and
PCRScript-asTFPI-2 plasmid serial dilutions, reflecting
copy numbers (1 × 100-1 × 106), were used to obtain a
standard curve correlating the copy number with the
threshold cycle number (Ct  values). Primers used for
amplification were as follows: TFPI-2, sense (5'-AAC GCC
AAC AAT TTC TAC ACC T-3') and antisense (5'-TAC TTT
TCT GTG GAC CCC TCAC-3'); asTFPI-2, sense (5'-AAC
GCC AAC AAT TTC TAC ACC T-3') and antisense (5'-CTT
TTG CGG ATT CAA C-3'). The cDNA products were quan-
tified from each sample in terms of the TFPI-2 and asTFPI-
2 copy numbers. As a control, cyclophilin A copy numbers
were obtained in a similar manner, and the relative copy
numbers of TFPI-2 and asTFPI-2 were calculated after nor-
malizing to 102 copies of cyclophilin A transcript for each
sample. To assure the primers specificity, the amplicons
were subjected to melting curve analysis, agarose gel elec-
trophoresis and nucleotide sequencing. Statistical analysis
was performed using GraphPad Prism software (San
Table 1: Oligonucleotide primers used to amplify asTFPI-2
Name of the primer Sequence (5' to 3')
FT2-CAP GAA AGC CGC GCA CCT CCT
FT2-SP1 CTG CAC CAT GGA CCC CGC T
FT2-Ex1A TGT CGA TTC TGC TGC TTT TCC TG
FT2-Ex1B CTG CAC TGG GCG ATG CTG CT
FT2-Ex1C CTG CTC AGG AGC CAA CAG
FT2-Int1A AGC CTC GCT TTC TCC AGG TCC
FT2-Int1B TAG GAG CTA CGC CTG ACC ACT T
FT2-EX2 AGG AAA TAA CGC GGA GAT CTG TCT
RT2-R1 TTG CTT CTT CCG AAT TTT CCG G
RHT-OD TTAA AAT TGC TTC TTC CGA AT
RT2-PAT GTC ATA TTA TTC TTC AGA TACMolecular Cancer 2007, 6:20 http://www.molecular-cancer.com/content/6/1/20
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Diego, CA) and a P-value < 0.05 was considered signifi-
cant.
Determination of mRNA stability
The relative stabilities of the wild-type TFPI-2 and as TFPI-
2 transcripts were assessed in HUVECs and Colo-205 cells,
respectively, following treatment of the cells with the tran-
scriptional inhibitor, actinomycin D. Briefly, subconflu-
ent cells were exposed to actinomycin D (5 µg/ml), and
the cells harvested for total RNA extraction at selected
times (0–24 h) following the addition of actinomycin D
[38]. RNA extraction, cDNA synthesis, and splice variant-
specific quantitative real-time PCR analysis were per-
formed as described above. The half-lives of TFPI-2 and
asTFPI-2 transcript was determined by calculating linear
regressions from a log-linear plot of mRNA expression
versus time (SigmaPlot).
Northern Blotting
Total RNA from HUVEC and Colo-205 cells was prepared
as described above. RNA (20 µg) was electrophoresed in a
1.2% agarose-formaldehyde gel, and transferred to a
nylon membrane overnight by capillary action. The mem-
brane was pre-hybridized at 65°C for 3 h and hybridized
at 42°C overnight with an asTFPI-2 cDNA probe labeled
with 32P-deoxycytidine triphosphate by random primed
labeling (Roche) according to the manufacturer's instruc-
tion. The membrane was washed sequentially with 2%
SSC containing 0.1% SDS for 15 minutes at room temper-
ature, 0.5% SSC containing 0.1% SDS for 20 min at room
temperature, and 0.1% SSC containing 1% SDS for 10
min at 65°C. The blot was then exposed to X-ray film at -
70°C for 24–72 h.
Western blot analysis
Various cells (~1 × 106) were lysed by sonication in 500 µl
of 125 mM Tris-HCl (pH 6.8) containing 2% SDS, 10%
glycerol, 50 mM sodium phosphate, 10 mM benzamidine
and 1 µg/ml aprotinin, centrifuged for 15 min at 10,000 ×
g at 4°C, and the supernatant recovered. The supernatants
were boiled for 3 min and subjected to SDS-PAGE in 4–
20% polyacrylamide gradient gels. Following electro-
phoresis, the proteins were electrotransferred to nitrocel-
lulose (NC) membranes and subsequently blocked with
5% calf serum/TBS/0.1% Tween 20 at 37°C for 2 h. The
NC membranes were then probed with rabbit anti-TFPI-2
IgG [21], washed, and incubated with diluted goat anti-
rabbit IgG-HRP. Immunoreactive proteins were identified
using a chemiluminescent reagent system. Separate blots
were treated with mouse monoclonal anti-alpha tubulin
antibody in order to demonstrate equal loading of the
proteins in the gel.
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